Aquestive Therapeutics (NASDAQ:AQST) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a sell rating to a hold rating in a report issued on Saturday morning.

AQST has been the subject of several other research reports. Piper Sandler raised their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Finally, Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Trading Down 0.9%

Shares of AQST stock opened at $4.22 on Friday. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $7.55. The business’s fifty day simple moving average is $4.22 and its 200-day simple moving average is $5.20. The company has a market cap of $515.01 million, a PE ratio of -5.41 and a beta of 1.61.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The firm had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million. On average, equities analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Invesco Ltd. lifted its holdings in shares of Aquestive Therapeutics by 20.2% during the fourth quarter. Invesco Ltd. now owns 64,993 shares of the company’s stock worth $420,000 after purchasing an additional 10,920 shares during the period. Voloridge Investment Management LLC acquired a new position in Aquestive Therapeutics in the 4th quarter worth approximately $1,254,000. Numerai GP LLC purchased a new position in Aquestive Therapeutics during the 4th quarter worth approximately $789,000. Occudo Quantitative Strategies LP purchased a new position in Aquestive Therapeutics during the 4th quarter worth approximately $365,000. Finally, Millennium Management LLC lifted its stake in Aquestive Therapeutics by 19.1% during the 4th quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock valued at $9,918,000 after acquiring an additional 246,040 shares during the period. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Aquestive reiterated FY?2026 revenue guidance of $46.0M–$50.0M and plans a commercial launch for Anaphylm with a ~75?rep sales force and an expanded medical affairs team — these items support near?term revenue upside if launch execution is successful. Aquestive plans 75?rep Anaphylm launch
• Neutral Sentiment: Company released Q4 results and an earnings?call presentation/transcript that provide more detail on revenue mix, commercialization plans and guidance; these materials will be used by investors to reassess model assumptions. Q4 2025 earnings call transcript
• Negative Sentiment: Q4 results missed expectations: EPS loss of $0.26 vs. consensus of ($0.13) and revenue slightly below estimates — the miss raises short?term earnings risk and increases scrutiny on margins and burn. Q4 results and estimates
• Negative Sentiment: Multiple law firms announced investigations and several class?action complaints were filed alleging that Aquestive misled investors about the timing of FDA approval for Anaphylm (PDUFA date-related disclosures). Legal exposure and potential damages or distraction to management are downside catalysts for the stock. Robbins LLP stockholder alert
• Negative Sentiment: Additional litigation notices/investigations were publicized today (Bernstein Liebhard, Holzer & Holzer, Gainey McKenna & Egleston, Faruqi & Faruqi), amplifying legal and reputational risk and likely adding selling pressure while matters progress. Bernstein Liebhard investor alert
• Negative Sentiment: Analyst commentary and a TipRanks note flagged new risk disclosures (AI execution risk and competitive threats) that could pressure future margins and R&D success probabilities. TipRanks AI execution risks

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.